Butrans Patch, Extended Release
Product Images NDC 59011-751

Product Visual Gallery

This gallery contains 31 technical images submitted to the FDA as part of the official labeling for Butrans (NDC 59011-751). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Knoa Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

302919 0c 5 Mcg Pouch

Butrans 5 mcg/hour buprenorphine transdermal system adhesive pouch label for a 5 mcg/hour dosage strength. The front includes prescribing information highlighting systemic delivery for seven days, warnings about serious respiratory risks, approved uses, and a lot/expiration area. The back of the pouch includes storage instructions and manufacturer details for Knoa Pharma LLC.*

FDA Label Image

302920 0c 10 Mcg Pouch

Butrans 10 mcg/hour (buprenorphine) transdermal patch label from Knoa Pharma LLC. The label indicates a single 10 mcg/hour extended-release transdermal system for buprenorphine, with instructions on use, storage, and dosage. Contains warning text regarding its use and emphasizes keeping out of reach of children.*

FDA Label Image

302921 0c 20 Mcg Pouch

Butrans 20 mcg/hour (buprenorphine) transdermal system label. The patch delivers 20 micrograms per hour of buprenorphine through a transdermal delivery system. Label includes instructions and warnings, dosage information, storage conditions, manufacturer Knoa Pharma LLC, and a barcode.*

FDA Label Image

302922 0d 5 Mcg Carton

Butrans 5 mcg/hour (buprenorphine) Transdermal System packaging label. The label shows a rectangular box design with dosage strength 5 mcg/hour prominently displayed alongside the brand name Butrans and the generic name buprenorphine. It specifies the patch as an extended-release transdermal system for systemic delivery over 7 days. The label includes regulatory information, warnings, and a Pharmacy Label area. The labeler is Knoa Pharma LLC.*

FDA Label Image

302923 0d 10 Mcg Carton

Packaging label for Butrans 10 mcg/hour (buprenorphine) Transdermal System by Knoa Pharma LLC. The label indicates this is a human prescription drug in patch, extended release form applied transdermally. It includes warnings that it is for patients requiring around-the-clock opioid analgesics and is not for as-needed pain relief. The label displays dosage strength, usage instructions, and regulatory information.*

FDA Label Image

302924 0d 20 Mcg Carton

Butrans 20 mcg/hour (buprenorphine) transdermal system carton label from Knoa Pharma LLC. The label details a 20 mcg/hour dosage strength in a patch, extended-release transdermal system. It includes usage instructions, NDC number 59011-752-04, safety warnings, and dispensing information. The packaging shows placement for bar code and tamper-evident areas.*

FDA Label Image

30300 0c 15 Mcg Pouch

Butrans 15 mcg/hour (buprenorphine) transdermal system label includes dosage information and warnings. It states systemic delivery of 15 mcg per hour for seven days, cautions against use for certain types of pain, and instructs to keep out of reach of children. The label shows it is a prescription drug, with storage temperature guidance and labeler Knoa Pharma LLC.*

FDA Label Image

303301 0d 15 Mcg Carton

Butrans 15 mcg/hour (buprenorphine) transdermal system packaging label. The label includes dosage strength, product form as an extended-release transdermal patch, the schedule III symbol, and the labeler Knoa Pharma LLC. It contains warnings about avoiding use in patients with certain breathing problems and instructions for the physician dispenser. The label also notes the package contains four disposable systems with bar code areas and no varnish coding areas marked.*

FDA Label Image

303368 0b 7.5 Mcg Pouch

Butrans 7.5 mcg/hour transdermal system patch packaging label showing the 7.5 microgram per hour strength of buprenorphine in an extended-release transdermal system. The label highlights the dosage strength, prescription status (Rx only), and provides warnings for serious breathing problems, with directions to keep out of reach of children. The labeler is Knoa Pharma LLC.*

FDA Label Image

303369 0c 7.5 Mcg Carton

Butrans 7.5 mcg/hour (buprenorphine) transdermal system packaging label for a patch extended release, labeled for seven-day use. The label displays dosage strength, administration route, active ingredient name, warnings about serious and life-threatening breathing problems, and use restriction to prescription only. The manufacturer is Knoa Pharma LLC, and NDC 59011-757-04 is printed on the label.*

FDA Label Image

Figure A Instructions (Butrans Instr Figa)

An instructional illustration showing recommended application sites for the Butrans buprenorphine transdermal patch on the human body. The diagram highlights four locations: the upper outer arm, the upper chest near the shoulder, the upper back near the shoulder blade, and the side of the chest below the armpit.*

FDA Label Image

Figure B Instructions (Butrans Instr Figb)

An illustration showing the upper back and shoulder area of a person with two adhesive patches applied side-by-side on the left shoulder blade. The image suggests proper placement for transdermal patches, likely representing Butrans buprenorphine extended-release patches.*

FDA Label Image

Figure C Instructions (Butrans Instr Figc)

An instructional black-and-white line drawing showing a person applying a transdermal patch to the upper chest area, near the shoulder. The image demonstrates the correct placement of a PATCH, EXTENDED RELEASE medication on the skin.*

FDA Label Image

Figure D Instructions (Butrans Instr Figd)

An instructional line drawing showing hands cutting a patch, likely demonstrating how to prepare a transdermal patch for use. The image suggests cutting the patch material into the desired size before application.*

FDA Label Image

Figure E Instructions (Butrans Instr Fige)

An instructional diagram showing a Butrans buprenorphine transdermal patch with labeled components: the patch, foil backing, and foil handle. The diagram illustrates the patch partially peeled from its foil backing using the foil handle for application.*

FDA Label Image

Figure F Instructions (Butrans Instr Figf)

An instructional illustration showing a hand peeling the backing off a transdermal patch, indicating the step for applying the patch to the skin.*

FDA Label Image

Figure G Instructions (Butrans Instr Figg)

An instructional diagram depicting a person applying a Butrans patch to the upper chest area, just below the collarbone. The image illustrates the correct placement method for the transdermal extended-release buprenorphine patch.*

FDA Label Image

Figure H Instructions (Butrans Instr Figh)

An instructional illustration showing proper application of a transdermal patch to the upper chest area. It depicts the hands holding and applying the patch to the skin near the shoulder. This image is relevant to transdermal patches like Butrans (buprenorphine) extended-release.*

FDA Label Image

Figure I Instructions (Butrans Instr Figi)

An instructional black-and-white line drawing illustrating the application of a transdermal patch on the upper chest area near the shoulder of a person's torso. The illustration shows a hand pressing the patch firmly against the skin, indicating proper placement and adhesion technique.*

FDA Label Image

Figure J Instructions (Butrans Instr Figj)

An instructional black-and-white line drawing showing hands peeling back the labeled wrapper of a transdermal patch. The visible label on the wrapper reads "STEP 1," indicating the first step in patch application.*

FDA Label Image

Figure K Instructions (Butrans Instr Figk)

An instructional illustration showing a hand peeling the protective liner off a Butrans transdermal patch, preparing to apply it to the skin of the lower leg or ankle area.*

FDA Label Image

Figure L Instructions (Butrans Instr Figl)

An instructional illustration showing two hands holding an unfolded paper or card. The paper displays the heading "STEP 3" and some text instructions, likely part of a step-by-step guide related to product use or application.*

FDA Label Image

Figure M Instructions (Butrans Instr Figm)

An instructional illustration depicting hands peeling a protective backing off a rectangular adhesive patch, which is presumably the Butrans buprenorphine transdermal patch. The drawing visually demonstrates how to remove the patch from its protective film before application.*

FDA Label Image

Figure N Instructions (Butrans Instr Fign)

An instructional illustration showing a hand holding a square patch over an open trash can, demonstrating proper disposal of the patch.*

FDA Label Image

Figure O Instructions (Butrans Instr Figo)

Instructional illustration showing a hand placing a rectangular transdermal patch into the lid of a toilet, demonstrating proper disposal of the Butrans (buprenorphine) extended-release transdermal patch.*

FDA Label Image

Butrans-structure (Butrans Structure)

Chemical structure of buprenorphine showing its molecular framework with various rings and functional groups, consistent with the active ingredient in Butrans transdermal patches.*

FDA Label Image

Figure-1 (Figure 1)

An illustration diagram showing the cross-sectional layers of a transdermal patch, labeled as 1. Backing Layer, 2. Overlapping Adhesive Film, 3. Separating Layer, 4. Drug/Polymer Adhesive Matrix, and 5. Peel-off Release Liner.*

FDA Label Image

Figure-2 (Figure 2)

A line graph showing the plasma concentration of Butrans (buprenorphine) 10 mcg/hour administered every 7 days for 3 cycles in 36 subjects. The graph displays concentration (pg/mL) on the Y-axis over time in days on the X-axis, highlighting fluctuations and a decline after patch removal at day 21.*

FDA Label Image

Figure-3 (Figure 3)

A line graph comparing the percentage of patients improved against the percent of reduction or improvement in pain between Butrans 10/20 and placebo groups. The graph shows two lines: one for placebo with circular markers and a dashed line, and one for Butrans 10/20 with square markers and a solid line, illustrating patient response to pain reduction over a range from >0% to 100% improvement.*

FDA Label Image

Figure-4 (Figure 4)

A line graph comparing the percentage of patients improved versus percent of reduction or improvement in pain for Butrans 5 mcg/h and Butrans 20 mcg/h transdermal patches. The graph shows two distinct lines for each strength, illustrating the relationship between pain reduction and patient improvement.*

FDA Label Image

Table-1 (Table 1)

A dosing recommendation table for Butrans (buprenorphine) transdermal patch showing starting doses based on previous opioid analgesic daily dose measured in oral morphine equivalents. For less than 30 mg, the recommended starting dose is 5 mcg/hour, and for 30-80 mg, it is 10 mcg/hour.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.